Model Medicines announces preclinical data in study of orally available lead therapeutic against COVID-19, in partnership with Scripps Research and Mount Sinai — Model Medicines

#1: Model Medicines’ CHEMprint™ AI/ML drug discovery platform discovered MDL-001 and identified that the drug was expected to inhibit SARS-CoV-2 replication via a broad spectrum antiviral target, indicating that MDL-001 may be effective against a broad array of RNA based viruses and SARS-CoV-2 varia

Read the full article here

Related Articles